Quick answer: Chronic Inflammatory Response Syndrome (CIRS) affects an estimated 24% of the population with the HLA-DR genetic susceptibility pattern, causes measurable multi-system inflammation driven by water-damaged building biotoxins (primarily mycotoxins and actinomycetes from mold), and responds to the evidence-based Shoemaker Protocol — a 12-step sequential treatment achieving complete remission in the majority of compliant patients.
What Is CIRS — and Why Is It Not Simply “Mold Allergy”?
Chronic Inflammatory Response Syndrome (CIRS) is a multi-system, multi-symptom illness acquired after exposure to the interior environment of water-damaged buildings (WDB). The term was coined and systematically characterized by Ritchie Shoemaker, MD, whose research since the late 1990s defines the condition’s immunogenetics, pathophysiology, biomarker profile, and treatment protocol.
CIRS is fundamentally different from mold allergy. IgE-mediated mold allergy involves a specific immune response to fungal proteins — measurable by skin prick testing or IgE RAST panels — and causes rhinitis, asthma, and urticaria in proportion to allergen exposure. CIRS is not IgE-mediated. It involves innate immune dysregulation triggered by biotoxins (primarily mycotoxins, but also lipopolysaccharides from gram-negative bacteria, endotoxins from actinomycetes, volatile organic compounds, beta-glucans, and microbial fragments) that persist in genetically susceptible individuals because their antigen-presenting cells cannot clear the biotoxins through normal HLA-mediated presentation.
The key genetic determinant: HLA-DR (human leukocyte antigen) haplotypes. Approximately 24% of the population carries HLA-DR patterns that cannot form antigen-antibody complexes with certain biotoxins — preventing immune memory formation and biotoxin clearance. In these individuals, biotoxins circulate, activate innate immune pathways, and drive continuous cytokine production long after leaving the exposure environment. The remaining 76% of the population clears biotoxins normally and does not develop CIRS.
The Pathophysiology: From Biotoxin to Multi-System Dysfunction
Biotoxins from water-damaged buildings trigger a cascade of dysregulation across multiple regulatory axes:
Innate immune activation: Biotoxins bind toll-like receptors (TLR2, TLR4) on monocytes, macrophages, and dendritic cells, triggering NF-κB activation and cytokine storm patterns. In CIRS, this innate immune activation becomes chronic — not because exposure continues, but because biotoxins are not cleared. Circulating pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, TGF-β1, MMP-9) perpetuate vascular, neurological, and endocrine dysfunction.
TGF-β1 dysregulation: Transforming growth factor beta-1 is one of the most diagnostically elevated markers in CIRS. Elevated TGF-β1 (>2,380 pg/mL) drives fibrosis, activates regulatory T-cells that suppress normal adaptive immune function, and suppresses the HPA axis. TGF-β1 elevation correlates with fatigue, cognitive impairment, and the immunosuppressed phenotype that makes CIRS patients vulnerable to opportunistic infections.
MMP-9 and blood-brain barrier disruption: Matrix metalloproteinase-9 (MMP-9) is proteolytically active against type IV collagen — the primary structural protein of basement membranes including BBB tight junctions. MMP-9 elevation (>332 ng/mL) in CIRS drives BBB permeability, allowing cytokines and biotoxins access to CNS tissue. This is the mechanism underlying the neurological symptoms — cognitive impairment, word retrieval difficulty, spatial disorientation, and the characteristic “brain fog” of CIRS.
MSH deficiency: Melanocyte-stimulating hormone (α-MSH, also written MSH) is a neuropeptide synthesized in the hypothalamus that regulates neuroinflammation, gut permeability, cortisol response, melatonin production, and antimicrobial peptide synthesis. Biotoxins suppress MSH production via POMC (proopiomelanocortin) pathway disruption. MSH levels <35 pg/mL (normal 35–81 pg/mL) are found in approximately 95% of CIRS patients and are associated with chronic pain, sleep disruption, gut permeability, and increased susceptibility to MARCoNS (see below).
VIP (Vasoactive Intestinal Peptide) deficiency: VIP is a neuropeptide critical for vascular tone regulation, pulmonary circulation, and anti-inflammatory signaling in the gut and CNS. VIP levels below 23 pg/mL (found in 40–60% of CIRS patients) cause pulmonary hypertension (measurable by PASP on echocardiogram), exercise intolerance, and fatigue. VIP deficiency also impairs regulatory T-cell function, perpetuating immune dysregulation.
Leptin and VEGF dysregulation: Leptin elevation (>7.0 ng/mL in men, >13.0 ng/mL in women) in CIRS drives appetite dysregulation, fatigue, and inflammatory signaling amplification. Concurrently, VEGF (vascular endothelial growth factor) is suppressed (<31 pg/mL) — impairing angiogenesis and tissue repair, causing the characteristic fatigue and reduced exercise capacity from inadequate capillary density in muscle tissue.
ACTH/cortisol axis suppression: CIRS typically produces a pattern of inappropriately low cortisol relative to ACTH stimulation — not classic Addison’s disease, but subclinical HPA axis dysregulation. Morning cortisol values of 8–14 mcg/dL with disproportionate fatigue suggest HPA involvement. This pattern is downstream of MSH suppression, which impairs CRH (corticotropin-releasing hormone) pulsatility.
The CIRS Symptom Cluster: 37 Symptoms Across 13 Clusters
The Visual Contrast Sensitivity (VCS) test — a validated neuropsychological test measuring the ability to detect contrast patterns at varying spatial frequencies — serves as a screening tool for CIRS with approximately 92% sensitivity in documented CIRS patients. The neural mechanism: biotoxins suppress retinal function via retrograde transport along the optic nerve, and reduced VCS scores are among the earliest detectable abnormalities. Online VCS tests (Surviving Mold’s approved testing protocol) provide a low-cost screening step before formal laboratory evaluation.
Shoemaker’s 37-symptom cluster assessment spans: fatigue, weakness, aching, muscle cramps, unusual pain, ice pick pain, headache, light sensitivity, red eyes, blurred vision, tearing, sinus problems, cough, shortness of breath, abdominal pain, diarrhea, joint pain, morning stiffness, memory impairment, difficulty concentrating, word retrieval difficulty, confusion/disorientation, skin sensitivity, mood swings, appetite swings, sweating, temperature dysregulation, excessive thirst, increased urination, static shocks, numbness and tingling, vertigo, metallic taste, and tremors. No single symptom is diagnostic — the pattern across clusters in the appropriate environmental context (documented WDB exposure) triggers clinical evaluation.
Laboratory Biomarker Profile for CIRS Diagnosis
The CIRS biomarker panel identifies specific hormonal, inflammatory, and vascular dysregulation patterns that collectively support diagnosis. Key markers (Shoemaker reference ranges):
TGF-β1: Normal <2,380 pg/mL. Elevated in most CIRS patients — often dramatically so (>5,000–15,000 pg/mL). Also elevated in systemic mastocytosis, Lyme disease, and post-COVID, providing convergent pathophysiology across these overlapping conditions.
MMP-9: Normal <332 ng/mL. Elevation drives neurological symptoms and BBB permeability. Curcumin, quercetin, and fish oil can reduce MMP-9 — explaining why anti-inflammatory supplementation produces partial CIRS symptom relief without full protocol adherence.
C4a: A complement split product (anaphylatoxin) that drives mast cell activation, histamine release, and vascular leakage. C4a >2,830 ng/mL is consistent with active biotoxin-driven innate immune activation. C4a has a short half-life and reflects current immune activation — unlike C3 or total complement, which are frequently normal in CIRS.
MSH (α-Melanocyte Stimulating Hormone): Normal 35–81 pg/mL. Low MSH (<35 pg/mL) in 95% of CIRS patients — the most consistently abnormal single marker in the CIRS panel. MSH level is the primary determinant of MARCoNS risk, sleep disruption, pain amplification, and gut permeability.
VIP: Normal 23–63 pg/mL. Low VIP drives pulmonary hypertension — measure PASP (pulmonary arterial systolic pressure) by echo at rest and post-exercise if VIP is persistently low after otherwise completing the Shoemaker protocol.
VEGF: Normal 31–86 pg/mL. Low VEGF explains exercise intolerance disproportionate to physical deconditioning — insufficient capillary recruitment.
ADH/osmolality: ADH (antidiuretic hormone) is frequently dysregulated in CIRS — the combination of low ADH + low osmolality produces excessive urination (polyuria) and electrolyte disturbances, while high ADH + high osmolality produces fluid retention and edema. Both patterns occur.
ACTH and cortisol: Morning ACTH and cortisol, interpreted together. Low cortisol relative to ACTH suggests peripheral HPA dysregulation. Reverse morning cortisol pattern (normal 8am value but evening elevation) suggests circadian HPA disruption.
HLA-DR haplotyping: Confirms genetic susceptibility. The most concerning haplotype — HLA-DR 4-3-53 — is associated with susceptibility to multiple biotoxin illnesses simultaneously. HLA-DR 11-3-52B is associated with susceptibility to Lyme disease persistence. Testing through specialty HLA laboratories.
MARCoNS: The Hidden Infection Driving Persistent CIRS
MARCoNS (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) is a deep nasal biofilm infection found in approximately 80% of CIRS patients with MSH below 35 pg/mL. Coagulase-negative Staphylococci (primarily S. epidermidis and S. hominis) are normally skin commensals, but in MSH-deficient patients, they colonize the deep nasal passages (ethmoid sinuses and posterior nasal space) and form biofilms that are protected from standard antibiotic courses.
MARCoNS produce hemolysins — exotoxins that directly cleave MSH and VIP peptide bonds, perpetuating the hormonal deficiencies driving CIRS. Without MARCoNS eradication, MSH cannot be restored regardless of other interventions. Detection requires deep nasal culture using a nasopharyngeal swab to the posterior turbinate — not standard anterior nasal swabs, which typically miss the deep biofilm. LabCorp and specialty CIRS laboratories offer MARCoNS-specific deep nasal culture protocols.
Treatment: BEG spray (Bactroban/mupirocin 0.2% + EDTA 0.01% + gentamicin 0.1%) applied to the nasal passages twice daily for 30 days is the standard eradication protocol. EDTA disrupts biofilm extracellular polysaccharide matrix, allowing mupirocin and gentamicin access to embedded bacteria. Repeat culture confirms eradication before proceeding. Colloidal silver nasal sprays show activity against MARCoNS biofilm in vitro; some clinicians use them as adjuncts or in antibiotic-resistant cases.
The Shoemaker Protocol: 12-Step Sequential Treatment
The Shoemaker Protocol requires strict sequential execution — each step addresses a specific pathophysiological component, and skipping steps or changing order reduces efficacy. The foundational principle: biotoxin binding and elimination must precede any hormonal restoration, because residual biotoxins will suppress restored neuropeptides.
Step 1 — Remove from exposure: Identify and permanently leave the water-damaged building. ERMI (Environmental Relative Moldiness Index) testing or HERTSMI-2 scoring quantifies mold burden using PCR analysis of floor and surface dust samples. ERMI scores >2 or HERTSMI-2 scores >11 indicate mold-impacted environments incompatible with recovery. There is no recovering in a biotoxin-impacted environment — this is non-negotiable.
Step 2 — Cholestyramine (CSM) binding: Cholestyramine, an anion exchange resin originally developed as a lipid-lowering agent, binds mycotoxins and biotoxins in the gut, preventing enterohepatic recirculation and facilitating fecal elimination. Dosing: 4g (one packet or one scoop) four times daily, 30 minutes before meals and bedtime, taken 4 hours apart from all other medications. Treatment duration: typically 1–4 months until symptom stabilization and biomarker normalization. Welchol (colesevelam) is a tolerated alternative (625mg tablets, better GI tolerability) though with somewhat reduced efficacy vs. CSM. Activated charcoal and zeolite have been used as alternatives for patients who cannot tolerate resin binders.
Step 3 — Eradicate MARCoNS: BEG spray protocol as described above. Confirm eradication by repeat deep nasal culture before proceeding.
Step 4 — Correct antigliadin antibodies: If elevated antigliadin IgA or IgG (celiac/NCGS overlap), institute strict gluten-free diet for 3–6 months before continuing.
Step 5 — Correct ADH/osmolality: If ADH and osmolality are abnormal, DDAVP (desmopressin, synthetic ADH analog) corrects the polyuria/polydipsia pattern and restores electrolyte balance. Monitoring sodium levels during DDAVP therapy is essential to prevent hyponatremia.
Step 6 — Correct MMP-9: Fish oil (2–4g EPA/DHA), curcumin (500–1,000mg twice daily with piperine), and statins (limited use) reduce elevated MMP-9, protecting BBB integrity and reducing neuroinflammation.
Step 7 — Correct VEGF: Low-intensity exercise (gradual reconditioning protocol) stimulates VEGF production. VIP (Step 12, below) also restores VEGF. Avoid high-intensity exercise until VEGF normalizes — excessive demand on insufficient capillary beds worsens fatigue and tissue hypoxia.
Step 8 — Correct androgens: If testosterone/DHEA are low (common in CIRS, downstream of MSH/HPA suppression), hormonal restoration at this stage — after biotoxin elimination and MARCoNS eradication — prevents premature hormonal repletion that would be suppressed by ongoing biotoxin burden.
Step 9 — Correct TGF-β1 with losartan: Losartan, an ARB (angiotensin receptor blocker), suppresses TGF-β1 signaling through AT1 receptor blockade and direct TGF-β1 pathway inhibition — independent of its antihypertensive mechanism. Shoemaker protocol uses losartan 25–50mg/day specifically for TGF-β1 normalization. Monitor potassium and renal function.
Step 10 — Correct leptin resistance: Leptin-sensitivity diet (low simple carbohydrate, elimination of processed foods, intermittent fasting) combined with exercise reduces hyperleptinemia. Berberine and metformin improve leptin receptor sensitivity.
Step 11 — Correct MSH with VIP: If MSH remains below 35 pg/mL after completing prior steps, intranasal VIP (compounded, 50 mcg per spray, 4 times daily) can restore MSH via its effect on hypothalamic POMC signaling. VIP is the final step because administering it in a biotoxin-laden environment or before MARCoNS eradication will be rapidly degraded by hemolysins.
Step 12 — VIP for pulmonary hypertension: If PASP remains elevated after MSH restoration, continued intranasal VIP specifically addresses pulmonary vascular tone normalization.
CIRS and Its Overlap Conditions
CIRS rarely presents in isolation in functional medicine clinical practice. Documented overlapping conditions include: Lyme disease and co-infections (the shared HLA-DR 11-3-52B susceptibility haplotype predisposes to both Lyme persistence and WDB biotoxin accumulation), MCAS (TGF-β1 and C4a elevation directly activate mast cells; MARCoNS hemolysins trigger mast cell degranulation), fibromyalgia (central sensitization driven by neuroinflammation from BBB disruption and MMP-9 elevation), chronic fatigue syndrome/ME-CFS (overlapping biomarker profiles — low MSH, VIP, VEGF), POTS (MSH deficiency impairs autonomic cardiovascular regulation), and post-COVID Long COVID (spike protein drives TGF-β1 and C4a elevation through mechanisms paralleling biotoxin-driven CIRS).
The clinical implication: a patient with apparent Lyme disease who has not recovered after appropriate antibiotic treatment may have co-existing CIRS from a water-damaged environment that is perpetuating immune dysregulation. Addressing CIRS in this context — identifying and leaving the biotoxin source, implementing the Shoemaker protocol — often allows Lyme recovery that was previously stalled despite adequate antimicrobial therapy.
Practical Remediation Guidance for Water-Damaged Buildings
Environmental assessment before attempting occupancy: ERMI testing (Environmental Relative Moldiness Index, EPA-validated PCR mold DNA quantification from dust samples) provides the most sensitive and reproducible measure of mold burden. ERMI values below −1 indicate low mold burden consistent with safe occupancy for CIRS-susceptible individuals; values above 2 indicate elevated mold burden; values above 5 are incompatible with recovery. The simplified HERTSMI-2 scoring assesses the 5 most clinically relevant ERMI species (Aspergillus penicillioides, Aspergillus versicolor, Chaetomium globosum, Stachybotrys chartarum, and Wallemia sebi) — a score >11 contraindicates occupancy.
Remediation requires professional remediation contractors following EPA/IICRC S520 guidelines — not DIY bleach treatment (which kills surface mold but does not address fungal spores, mycotoxins embedded in porous building materials, or the ERMI-quantified DNA burden). Remediation effectiveness must be confirmed by post-remediation ERMI or HERTSMI-2 testing before reoccupancy. If remediation cannot reduce ERMI to safe levels, permanent relocation is required for CIRS recovery.
Frequently Asked Questions About CIRS
How long does recovery from CIRS take?
Recovery timeline varies by severity, compliance with the Shoemaker Protocol, and duration of prior exposure. Patients who identify exposure early, leave the biotoxin environment promptly, and complete the full protocol in a clean environment often show significant biomarker normalization within 3–6 months and symptom resolution within 6–12 months. Patients with years of exposure, multiple co-infections (Lyme + MARCoNS), or prior partial treatments may require 12–24 months of systematic protocol adherence. Attempting to shortcut the sequential protocol invariably prolongs recovery.
Does CIRS resolve completely or require lifelong treatment?
Most CIRS patients achieve complete or near-complete remission with full protocol completion, as evidenced by normalized biomarkers (TGF-β1, MMP-9, C4a, MSH, VIP, VEGF) and return to full function. However, genetic HLA-DR susceptibility is permanent — re-exposure to water-damaged buildings can restart the cascade. CIRS-recovered patients must maintain environmental vigilance (ERMI testing of any new residence or workplace) and recognize early relapse symptoms, particularly the characteristic cognitive symptoms, as a signal to reassess their environment.
Can I do the CIRS protocol without a physician?
No — the Shoemaker Protocol involves prescription medications (cholestyramine, losartan, DDAVP, VIP) that require physician supervision. Additionally, the protocol requires interpretation of specialized laboratory markers, monitoring for medication side effects, and clinical judgment about sequencing adjustments based on individual biomarker trajectories. Attempting to self-treat CIRS without physician oversight risks incomplete treatment (leaving residual biotoxin burden or untreated MARCoNS), medication errors, and prolonged illness. Seek a Shoemaker-certified or CIRS-literate practitioner.
Is CIRS the same as Sick Building Syndrome?
Sick Building Syndrome (SBS) is a broader occupational health term describing non-specific symptoms (headache, fatigue, respiratory irritation) occurring in building occupants without a specific identifiable illness — typically resolving rapidly upon leaving the building. CIRS is a specific, immunogenetically mediated illness with defined biomarkers, defined genetic susceptibility, and defined treatment protocol — it persists after leaving the building because biotoxins have been internalized and cannot be self-cleared due to HLA-DR susceptibility. SBS affects occupants temporarily; CIRS persists and progressively worsens without specific treatment.
Biotoxin illness and CIRS represent one of the most underdiagnosed conditions in conventional medicine — yet one of the most systematically treatable when properly identified. Our functional medicine team at The Private Practice offers comprehensive CIRS evaluation including the full Shoemaker biomarker panel, HLA-DR haplotyping, MARCoNS culture, VCS testing, and coordinated protocol management. Call us at (810) 206-1402 to begin your evaluation.